In 2020, the U.S. neurology devices market size was valued at $4.8 billion, and there were over 726,000 neurological procedures performed. The market size is expected to increase at a growth rate of 6.9% to reach $7.6 billion in 2026. Throughout this medical market research, we analyzed 44 neurological device companies across the United States

Industry Trends One of the major drivers for the neurological devices market is the patient and physicians demand for minimally invasive procedures. This has been driving the growth in aspiration thrombectomy and neurovascular stenting and the decline of and aneurysm clipping procedures treatments. With the growth in these markets, the market value for ubiquitous neurovascular

The full report suite on the European market for neurological devices includes cerebrospinal fluid management devices, detachable coils, liquid embolics, neurovascular guidewires, neurovascular catheters, neurovascular stents, aneurysm clips, intrasaccular stents, neurovascular thrombectomy devices, ultrasonic aspirators, neuromodulation devices, intrathecal pumps, stereotactic devices and transcranial magnetic simulators. The market for balloon occlusion is discussed separately in the

Embolization is a non-surgical, minimally invasive procedure that involves the selective occlusion of blood vessels by purposely introducing emboli. The procedure is a minimally invasive alternative to open surgery and is performed by interventional radiologists and interventional neuroradiologists. Liquid embolic products are used for the embolization of both aneurysms (weakened balloon-like portions of a vessel) and arterio-venous malformations (AVMs).

Liquid embolics currently on the market include N-butyl cyanoacrylate (NBCA) (TRUFILL®) and an ethylene-vinyl alcohol copolymer (Onyx®). These agents are injected through microcatheters and act like glue in abnormal blood vessels. When they contact blood they solidify and obstruct the vessel lumen therefore blocking the flow of blood through malformed blood vessels and reducing the risk of rupture. The surgeon performing the procedure must flush the catheter before and after injecting the NBCA to prevent the liquid agent from sticking to the catheter. Thus this procedure requires a highly skilled physician. This is often done prior to the removal of these vessels in order to simplify the surgical procedure.

In 2012, the Chinese market for neurological devices was valued at over $528 million. The Chinese market for neurological devices includes fixed pressure CSF shunts, adjustable pressure CSF shunts, bare platinum detachable coils, coated detachable coils, liquid embolics, neurovascular catheters, neurovascular stents, neurovascular guide wires, deep brain stimulators (DBS), spinal cord stimulators (SCS), sacral nerve stimulators (SNS), intrathecal pumps, frame-based stereotactic systems, frameless stereotactic systems and aneurysm clips. Market growth will be driven by the continued acceptance of aneurysm treatment procedures, arteriovenous malformation (AVM) treatment procedures and frameless stereotactic treatment for cranial tumors.

Over the past several years, there has been a transition in interventional neuroradiology from surgical to endovascular techniques. This has caused a conversion from aneurysm clipping to endovascular coiling. Research has supported a shift toward treatment of acutely ruptured intracranial aneurysms by endovascular occlusion. There have been many contentious issues pertaining to treatment recommendations for endovascular coiling that include treatment timing, the incidence of procedural complications, anatomical cure rates and recurrence. Coils are used to treat aneurysms and fistulas in the brain in order to prevent rupture. The coil helps stop the flow of blood into the aneurysm sac, thereby reducing the likelihood of the aneurysm rupturing.